MannKind Corporation in Valencia is enrolling patients in two twelve-month Phase 3 clinical trials for its Technosphere Insulin product. Technosphere, a form of inhalable insulin, would compete with a similar product designed by Pfizer which was recently approved by the Food and Drug Administration. The potential inhalable insulin market is estimated to be billions of dollars. The last remaining major trial for Technosphere is scheduled to begin this coming summer.
